脑电生物反馈联合氨磺必利在改善精神分裂症患者认知功能中的应用价值

Application value of electroencephalogram biofeedback combined with amisulpride in improving cognitive function in patients with schizophrenia

摘要:

目的 探讨脑电生物反馈联合氨磺必利对精神分裂症（SC）患者的治疗效果。方法 选取2022年1月至2024年1月萍乡矿业集团有限责任公司总医院收治的80例SC患者，按随机数字表法将其分为两组。对照组（n=40）采用氨磺必利治疗，观察组（n=40）采用氨磺必利联合脑电生物反馈治疗。比较两组临床疗效、认知功能〔威斯康星卡片分类测验（WCST）〕、临床症状〔阳性和阴性精神症状评定量表（PANSS）〕、神经递质及不良反应。结果 观察组治疗总有效率（95.00%）高于对照组（75.00%）（P＜0.05）。治疗后，观察组的完成分类数评分〔（3.98±0.82）分〕及总正确数评分〔（3.85±0.42）分〕高于对照组（P＜0.05）；总应答数评分〔（94.25±9.82）分〕、持续错误数评分〔（414.63±3.43）分〕及总错误数评分〔（69.26±10.34）分〕均低于对照组（P＜0.05）；阳性症状评分〔（12.88±2.16）分〕、阴性症状评分〔（14.63±2.36）分〕、一般病理评分〔（28.85±5.73）分〕及PANSS总分〔（56.36±7.25）分〕均低于对照组（P＜0.05）；观察组脑源性神经营养因子水平（31.88±6.54）μg/L高于对照组（P＜0.05）；同型半胱氨酸水平（5.07±1.16）μmol/L、神经元特异性烯醇化酶水平（8.35±1.52）μg/L均低于对照组（P＜0.05）。两组不良反应发生率对比无统计学差异（P＞0.05）。结论 脑电生物反馈结合氨磺必利在改善SC患者认知功能、临床症状、神经递质水平方面应用效果较为显著，且较为安全。

Abstract:

Objective To explore the therapeutic effect of electroencephalogram (EEG) biofeedback combined with amisulpride on patients with schizophrenia (SC).Methods A total of 80 patients with SC admitted in General Hospital of Pingxiang Mining Group Co. from January 2022 to January 2024 were selected and divided into two groups according to the random number table method. The control group (n=40) was treated with amisulpride, and the observation group (n=40) was treated with EEG biofeedback and amisulpride. The clinical efficacy, cognitive function 〔Wisconsin Card Sorting Test (WCST)〕, clinical symptoms 〔positive and negative psychiatric symptom rating scale (PANSS)〕, neurotransmitters and adverse reactions were compared between the two groups.Results The total effective rate of the observation group (95.00%) was higher than that of the control group (75.00%) (P＜0.05). After treatment, the completion classification score (3.98±0.82) and total positive score (3.85±0.42) of the observation group were higher than those of the control group (P＜0.05); The total number of answers score (94.25±9.82), the continuous number of errors score (14.63±3.43), and the total number of errors score (69.26±10.34) were all lower than those in the control group (P＜0.05); The positive symptom score (12.88±2.16), negative symptom score (14.63±2.36), general pathological score (28.85±5.73), and PANSS total score (56.36±7.25) were all lower than those in the control group (P＜0.05); The level of brain-derived neurotrophic factor in the observation group (31.88±6.54) μg/L was higher than that in the control group (P＜0.05); The levels of homocysteine (5.07±1.16) μmol/L and neuron specific enolase (8.35±1.52) μg/L were lower than those in the control group, with statistical differences (P＜0.05). There was no statistically significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion The application effect of EEG biofeedback combined with amisulpride in improving cognitive function, clinical symptoms and neurotransmitter levels in patients with SC is significant and safe.